Protego Bio

Protego focuses on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases. We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases. Our approach builds on the proven pharmacological chaperones approach previously exemplified by tafamidis, which was discovered and developed by our cofounders Dr. Jeffery W. Kelly and Dr. Richard Labaudiniere, for the treatment of transthyretin amyloidosis

Protego bio operates in the Biotechnology research industry.

Protego bio's revenue is 11m - 100m

Protego bio has 11 - 50 employees.